Based on the results of our preclinical investigation, we further analyzed whether clinical correlations occur between the expression levels of resistin, CXCL5, and ERK phosphorylation in breast cancer patients by immunohistochemistry (Fig. 6A). Here, RETN is linked to breast cancer.